EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Klinische Studie (Phase I)Open Access · CC BY-NC-ND 4.0

Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab

Xuefeng Wang, Tingyi Li, Robbert J C Slebos, Ritu Chaudhary, Jose A Guevara-Patino, Marcelo Bonomi, Nabil F Saba, Christine H Chung

Cancer Immunology, Immunotherapy · 2025

DOI: 10.1007/s00262-025-03993-6 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Xuefeng Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. xue…. Hauptthemen laut MEDLINE: Nivolumab, Squamous Cell Carcinoma of Head and Neck, Cetuximab, Head and Neck Neoplasms. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCR NIH HHS, National Institute of Health, James and Esther King Biomedical Research Grant.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immunotherapy holds significant promise for treating head and neck squamous cell carcinoma (HNSCC), yet responses are limited to a subset of patients. This research investigates whether analyzing the peripheral T-cell receptor (TCR) repertoire could help identify patients who are more likely to benefit from a combination treatment of cetuximab and nivolumab. We report here updated correlative analysis using all samples profiled with deep immunoSEQ assay to study the peripheral TCR repertoires in peripheral blood mononuclear cells from patients enrolled in a phase I/II trial (NCT03370276). TCR repertoires were analyzed in 67 patients. Of these, 64 had available baseline data. Overall, our findings confirm that a more polyclonal peripheral TCR repertoire is associated with improved response to concurrent cetuximab and nivolumab in HNSCC. While the baseline productive Simpson clonality did not reach statistically significant differences in response groups, significant differences were observed within the HPV-negative subgroup and among patients who had received previous ICI therapy. Additionally, the TCR diversity at baseline and early follow-up was associated with overall survival. TRBV/TRBJ gene usage analysis also identified specific gene pairs associated with patient outcomes. Furthermore, our analysis indicates that the TCR clonality patterns are modulated by prior treatment exposures and tumor HPV status, suggesting a cohort expansion within these subgroups for further validation. Together, this study demonstrates the feasibility of leveraging the peripheral T-cell repertoire profiling and clonality dynamics as predictive biomarkers for immunotherapy efficacy in HNSCC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabSquamous Cell Carcinoma of Head and NeckCetuximabHead and Neck NeoplasmsReceptors, Antigen, T-CellAntineoplastic Combined Chemotherapy ProtocolsT-LymphocytesHumansMaleFemaleMiddle AgedAgedAdultClinical Relevance

Stichwörter der Autor:innen

CetuximabHead and neck squamous cell carcinomaImmunotherapyNivolumabPeripheral bloodT-cell repertoire

Substanzen

NivolumabCetuximabReceptors, Antigen, T-Cell

Autor:innen und Institutionen

  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA. xuefeng.wang@moffitt.org.
  • Immuno-Oncology Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA. xuefeng.wang@moffitt.org.
  • Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, 12902 Magnolia Drive, Tampa, FL, 33612, USA.
  • Department of Head and Neck-Endocrine Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
  • Department of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, 33612, USA.
  • Department of Internal Medicine, The Ohio State University Wexner Medical Center and Comprehensive Cancer Center, Columbus, OH, 43210, USA.

Förderung

  • NIDCR NIH HHS
  • National Institute of Health
  • James and Esther King Biomedical Research Grant

Zitieren

APA

Wang, X., Li, T., Slebos, R. J. C., Chaudhary, R., Guevara-Patino, J. A., Bonomi, M., Saba, N. F., & Chung, C. H. (2025). Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-03993-6

Vancouver

Wang X, Li T, Slebos RJC, Chaudhary R, Guevara-Patino JA, Bonomi M, et al. Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-03993-6

BibTeX
@article{Wang2025,
  author = {Wang, Xuefeng and Li, Tingyi and Slebos, Robbert J C and Chaudhary, Ritu and Guevara-Patino, Jose A and Bonomi, Marcelo and Saba, Nabil F and Chung, Christine H},
  title = {Clinical significance of peripheral T-cell repertoire in head and neck squamous cell carcinoma treated with cetuximab and nivolumab},
  journal = {Cancer Immunology, Immunotherapy},
  year = {2025},
  doi = {10.1007/s00262-025-03993-6}
}
Kostenlos starten →